CRC Research Update

  • TRIAL DATA

    Immune checkpoint inhibitors show promise in hard-to-treat rectal cancer subtype

    A new meta-analysis examined immune checkpoint inhibitor combinations as neoadjuvant therapy for locally advanced rectal cancer with proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumors—a subtype that typically does not respond well to immunotherapy. (Clinical Colorectal Cancer)

  • RESEARCH

    Selenium nanoparticles selectively target KRAS G13D mutation

    Researchers developed selenium nanoparticles that specifically inhibit tumors driven by the KRAS G13D mutation—a variant that currently has no approved targeted therapies—by upregulating the tumor suppressor GPX2 and blocking metastasis pathways. (Advanced Science)

  • LIVING WITH CRC

    What helps survivors use their care plans after treatment

    Interviews with 30 breast and colorectal cancer survivors found that survivorship care plans were most helpful when survivors discussed them with their primary care providers and found the information reassuring and relevant to their follow-up care. (Canadian Oncology Nursing Journal)

  • LIVING WITH CRC

    Study identifies risk factors for irinotecan liver toxicity

    A retrospective study of 229 cancer patients receiving irinotecan chemotherapy identified key risk factors for hepatotoxicity, which could help clinicians monitor and manage this side effect more effectively. (Frontiers in Oncology)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Research continues to expand our understanding of treatment options and quality of life for the CRC community.